Aspire Biopharma Holdings, Inc. cash flow to debt ratio of -355.54% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Aspire Biopharma Holdings, Inc.'s free cash flow has decreased 1.76K% from $-265.19K last year to $-4.92M, signaling decreasing performance

Aspire Biopharma Holdings, Inc.'s debt to equity ratio is 0.39, which means that the company's assets are healthy financed, signaling financial stability.

Aspire Biopharma Holdings, Inc.'s debt has increased relative to shareholder equity from -0.82 last year to 0.39 today, signaling weakened financials

Aspire Biopharma Holdings, Inc. has negative EBITDA, making leverage ratio unreliable

Aspire Biopharma Holdings, Inc.'s interest coverage ratio is -0.55, which means that the company struggles to meet interest obligations, signaling financial risk.

Aspire Biopharma Holdings, Inc. has insufficient data to evaluate this check.

Aspire Biopharma Holdings, Inc.'s short-term liabilities of $7.59M exceed its short-term assets of $1.31M, signaling financial risk

Aspire Biopharma Holdings, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Aspire Biopharma Holdings, Inc.'s return on equity of 199.43%, is higher than 15.00%, indicating good performance

Aspire Biopharma Holdings, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Aspire Biopharma Holdings, Inc. has insufficient public price history to evaluate earnings stability.

Aspire Biopharma Holdings, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Aspire Biopharma Holdings, Inc. has negative free cash flow, indicating cash burn

Aspire Biopharma Holdings, Inc.'s yearly earnings has decreased 95.27% since last year from $-12.54M to $-24.48M, signaling decreasing performance

Aspire Biopharma Holdings, Inc.'s yearly revenue has increased % since last year from $0.00 to $6.20K, signaling increasing performance

ROIC -99.58% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Aspire Biopharma Holdings, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Aspire Biopharma Holdings, Inc. has insufficient public price history to evaluate revenue consistency.

Aspire Biopharma Holdings, Inc. has insufficient public price history to evaluate ROE consistency.

Aspire Biopharma Holdings, Inc. has insufficient data to evaluate this check.

Aspire Biopharma Holdings, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Aspire Biopharma Holdings, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Aspire Biopharma Holdings, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Aspire Biopharma Holdings, Inc. has insufficient data to evaluate this check.

Aspire Biopharma Holdings, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Aspire Biopharma Holdings, Inc. has a price-to-book ratio of 3.01x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Aspire Biopharma Holdings, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue